[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 31 of about 31
1. Vasey PA, Atkinson R, Coleman R, Crawford M, Cruickshank M, Eggleton P, Fleming D, Graham J, Parkin D, Paul J, Reed NS, Kaye SB: Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer. Br J Cancer; 2001 Jan;84(2):170-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer.
  • A prospective, non-randomized, multicentre, open, dose-finding study of a carboplatin-docetaxel (C-D) combination as first-line chemotherapy in FIGO stage Ic-IV epithelial ovarian cancer.
  • 139 eligible patients (Pts) (median age 56 years, range 28-85) were given a total of 750 cycles of chemotherapy in 5 cohorts: Co1, 32 pts, 169 cycles (C at AUC 5 + D 60 mg/m(2)); Co2, 22 pts, 122 cycles (5 + 75), Co3, 29 pts, 156 cycles (6 + 75), Co4, 27 pts, 146 cycles (7 + 75), Co5, 30 pts, 157 cycles (6 + 85).
  • There were 2 probable treatment-related deaths.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ovarian Neoplasms / drug therapy. Paclitaxel / analogs & derivatives. Taxoids
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carboplatin / administration & dosage. Carboplatin / adverse effects. Constipation / chemically induced. Diarrhea / chemically induced. Dose-Response Relationship, Drug. Fatigue / chemically induced. Female. Hematologic Diseases / chemically induced. Humans. Middle Aged. Nausea / chemically induced. Neoplasm Staging. Prospective Studies. Survival Analysis. Treatment Outcome. Vomiting / chemically induced

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Cancer Research Campaign.
  • [Cites] Nat Med. 1996 Sep;2(9):1035-7 [8782464.001]
  • [Cites] Nat Med. 1996 Sep;2(9):1033-5 [8782463.001]
  • [Cites] Semin Oncol. 1996 Oct;23(5 Suppl 12):48-54 [8941410.001]
  • [Cites] Br J Cancer. 1997;75(2):287-94 [9010040.001]
  • [Cites] Br J Cancer. 1997;75(3):417-22 [9020489.001]
  • [Cites] Semin Oncol. 1997 Feb;24(1 Suppl 2):S2-34-S2-37 [9045334.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):1953-64 [9164207.001]
  • [Cites] Ann Oncol. 1997 Apr;8(4):351-4 [9209664.001]
  • [Cites] Ann Oncol. 1997 Apr;8(4):355-61 [9209665.001]
  • [Cites] Oncogene. 1997 Jul 3;15(1):45-52 [9233776.001]
  • [Cites] Eur J Cancer. 1997 Apr;33(4):592-5 [9274440.001]
  • [Cites] Cancer Chemother Pharmacol. 1998;41(2):161-6 [9443630.001]
  • [Cites] Eur J Cancer. 1997 Nov;33(13):2167-70 [9470802.001]
  • [Cites] Br J Cancer. 1998 May;77(10):1686-8 [9635850.001]
  • [Cites] Br J Cancer. 1998 Dec;78(11):1479-87 [9836481.001]
  • [Cites] Oncogene. 1999 Apr 8;18(14):2335-41 [10327053.001]
  • [Cites] J Clin Oncol. 1999 Jul;17(7):2069-80 [10561260.001]
  • [Cites] J Natl Cancer Inst. 2000 May 3;92(9):699-708 [10793106.001]
  • [Cites] Clin Sci. 1969 Aug;37(1):169-80 [4980763.001]
  • [Cites] Cancer. 1981 Jan 1;47(1):207-14 [7459811.001]
  • [Cites] J Clin Oncol. 1989 Nov;7(11):1748-56 [2681557.001]
  • [Cites] J Clin Oncol. 1991 Jul;9(7):1138-50 [1904477.001]
  • [Cites] Cancer. 1993 Jan 15;71(2 Suppl):517-23 [8420671.001]
  • [Cites] J Natl Cancer Inst Monogr. 1993;(15):107-15 [7912516.001]
  • [Cites] J Clin Oncol. 1995 Mar;13(3):726-32 [7884432.001]
  • [Cites] Diabet Med. 1994 Nov;11(9):872-6 [7705025.001]
  • [Cites] N Engl J Med. 1996 Jan 4;334(1):1-6 [7494563.001]
  • [Cites] Neurology. 1996 Jan;46(1):104-8 [8559354.001]
  • [Cites] Neurology. 1996 Jan;46(1):108-11 [8559355.001]
  • [Cites] J Clin Oncol. 1996 May;14(5):1545-51 [8622070.001]
  • [Cites] Cancer Res. 1996 Feb 15;56(4):689-93 [8630996.001]
  • [Cites] J Clin Oncol. 1996 Jun;14(6):1895-902 [8656258.001]
  • [Cites] Anticancer Drugs. 1996 Aug;7 Suppl 2:17-9 [8862705.001]
  • (PMID = 11161372.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  • [Other-IDs] NLM/ PMC2363708
  •  go-up   go-down


2. Windbichler GH, Hausmaninger H, Stummvoll W, Graf AH, Kainz C, Lahodny J, Denison U, Müller-Holzner E, Marth C: Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial. Br J Cancer; 2000 Mar;82(6):1138-44
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial.
  • Intraperitoneal treatment with interferon-gamma (IFN-gamma) has been shown to achieve surgically documented responses in the second-line therapy of ovarian cancer.
  • To assess its efficacy in the first-line therapy, we conducted a randomized controlled trial with 148 patients who had undergone primary surgery for FIGO stage Ic-Illc ovarian cancer.
  • Progression-free survival at 3 years was improved from 38% in controls to 51% in the treatment group corresponding to median times to progression of 17 and 48 months (P= 0.031, relative risk of progression 0.48, confidence interval 0.28-0.82).
  • Thus, with acceptable toxicity, the inclusion of IFN-gamm in the first-line chemotherapy of ovarian cancer yielded a benefit in prolonging progression-free survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Interferon-gamma / therapeutic use. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Disease Progression. Disease-Free Survival. Female. Humans. Injections, Subcutaneous. Middle Aged. Prospective Studies

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell Immunol. 1983 Jul 15;79(2):396-402 [6307534.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7556-61 [9636188.001]
  • [Cites] Cancer Res. 1986 Mar;46(3):1142-7 [3080233.001]
  • [Cites] Cancer Res. 1986 Oct;46(10):5401-5 [3093063.001]
  • [Cites] J Clin Oncol. 1988 Mar;6(3):434-45 [3127550.001]
  • [Cites] J Clin Oncol. 1988 Apr;6(4):689-95 [3128649.001]
  • [Cites] Immunobiology. 1987 Dec;176(1-2):85-95 [3129362.001]
  • [Cites] Am J Clin Oncol. 1988 Aug;11(4):465-9 [3136645.001]
  • [Cites] Cancer Res. 1989 Dec 1;49(23):6538-42 [2510928.001]
  • [Cites] Cancer Res. 1990 Nov 1;50(21):7037-41 [2119884.001]
  • [Cites] Cancer Res. 1990 Nov 15;50(22):7318-23 [2121337.001]
  • [Cites] J Natl Cancer Inst. 1991 Jan 2;83(1):37-42 [1984515.001]
  • [Cites] Cancer Res. 1991 Sep 1;51(17):4575-80 [1678683.001]
  • [Cites] Cancer Res. 1991 Dec 15;51(24):6643-9 [1742738.001]
  • [Cites] Int J Cancer. 1992 Apr 22;51(1):42-6 [1563843.001]
  • [Cites] Eur J Cancer. 1994;30A(4):520-5 [8018412.001]
  • [Cites] Immunity. 1994 Sep;1(6):447-56 [7895156.001]
  • [Cites] N Engl J Med. 1996 Jan 4;334(1):1-6 [7494563.001]
  • [Cites] J Clin Oncol. 1996 Feb;14(2):343-50 [8636742.001]
  • [Cites] Adv Immunol. 1996;62:61-130 [8781267.001]
  • [Cites] Int J Cancer. 1996 Sep 17;67(6):826-30 [8824555.001]
  • [Cites] Annu Rev Immunol. 1997;15:749-95 [9143706.001]
  • [Cites] Br J Cancer. 1997;76(10):1328-32 [9374379.001]
  • [Cites] Cancer Res. 1985 Sep;45(9):4447-53 [4028027.001]
  • (PMID = 10735496.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] SCOTLAND
  • [Chemical-registry-number] 82115-62-6 / Interferon-gamma; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; CP protocol
  • [Other-IDs] NLM/ PMC2363351
  •  go-up   go-down


3. Harris MA, Delap LM, Sengupta PS, Wilkinson PM, Welch RS, Swindell R, Shanks JH, Wilson G, Slade RJ, Reynolds K, Jayson GC: Carcinosarcoma of the ovary. Br J Cancer; 2003 Mar 10;88(5):654-7
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinosarcoma of the ovary.
  • We report our experience in the management of patients with carcinosarcoma of the ovary, a rare but aggressive variant of ovarian cancer.
  • Thirty-two patients (80%) presented with FIGO stage III or IV disease.
  • Chemotherapy was given to 32 patients (80%) of whom 26 (81%) received platinum-based regimens.
  • Of the 19 patients who had a CR, PR or stable disease after chemotherapy or were unevaluable (stage Ic), the median survival was 29.6 months.
  • Currently, seven patients are still alive although one has cancer.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinosarcoma / drug therapy. Ovarian Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 1989 May;33(2):212-21 [2539317.001]
  • [Cites] Am J Surg Pathol. 1995 Jun;19(6):666-74 [7755153.001]
  • [Cites] Ann Oncol. 1995 Oct;6(8):755-8 [8589011.001]
  • [Cites] Gynecol Oncol. 1989 Feb;32(2):228-32 [2535999.001]
  • [Cites] Arkh Patol. 1978;40(4):59-65 [678156.001]
  • [Cites] Obstet Gynecol Surv. 1983 Sep;38(9):537-45 [6312386.001]
  • [Cites] Gynecol Oncol. 1984 Jul;18(3):278-92 [6086467.001]
  • [Cites] Minerva Ginecol. 1999 Nov;51(11):445-8 [10726444.001]
  • (PMID = 12618869.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC2376340
  •  go-up   go-down


Advertisement
4. Oei AL, Verheijen RH, Seiden MV, Benigno BB, Lopes A, Soper JT, Epenetos AA, Massuger LF: Decreased intraperitoneal disease recurrence in epithelial ovarian cancer patients receiving intraperitoneal consolidation treatment with yttrium-90-labeled murine HMFG1 without improvement in overall survival. Int J Cancer; 2007 Jun 15;120(12):2710-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decreased intraperitoneal disease recurrence in epithelial ovarian cancer patients receiving intraperitoneal consolidation treatment with yttrium-90-labeled murine HMFG1 without improvement in overall survival.
  • This study analyzes the site of disease recurrence in ovarian cancer patients to assess the influence of a single intraperitoneal (IP) administration of yttrium-90-labeled murine monoclonal antibody HMFG1 ((90)Y-muHMFG1) on the pattern of disease recurrence.
  • In a large phase III trial ovarian cancer patients in complete clinical remission with FIGO stage Ic-IV were randomized between standard treatment plus a single IP (90)Y-labeled muHMFG1 versus standard treatment alone after negative second-look laparoscopy.
  • Significantly fewer IP (p < 0.05) and more extraperitoneal (p < 0.05) relapses occurred in the active treatment arm.
  • Time to IP recurrence was significantly longer (p = 0.0019) and time to extraperitoneal recurrence was significantly shorter for the active treatment arm (p < 0.001).
  • Although, there is no survival benefit for IP radioimmunotherapy as consolidation treatment for epithelial ovarian cancer, we found an improved control of IP disease, that was offset by increased extraperitoneal recurrences.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Ovarian Neoplasms / drug therapy. Peritoneal Diseases / prevention & control
  • [MeSH-minor] Adult. Aged. Animals. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Epithelial Cells / pathology. Female. Follow-Up Studies. Humans. Injections, Intraperitoneal. Kaplan-Meier Estimate. Laparoscopy. Mice. Middle Aged. Peritoneal Neoplasms / prevention & control. Peritoneal Neoplasms / secondary. Secondary Prevention. Treatment Outcome. Yttrium Radioisotopes

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Peritoneal Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17354223.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Yttrium Radioisotopes; 0 / pemtumomab
  •  go-up   go-down


5. Högberg T, Glimelius B, Nygren P, SBU-group. Swedish Council of Technology Assessment in Health Care: A systematic overview of chemotherapy effects in ovarian cancer. Acta Oncol; 2001;40(2-3):340-60
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A systematic overview of chemotherapy effects in ovarian cancer.
  • A systematic review of chemotherapy trials in several tumour types was performed by The Swedish Council of Technology Assessment in Health Care (SBU).
  • This overview on chemotherapy for epithelial ovarian cancer is based on a total of 176 scientific reports.
  • The conclusions reached can be summarized into the following points: Radically operated patients with low-risk early ovarian cancer (stage IA or IB non-clear-cell well-differentiated carcinomas or borderline tumours) have a very good prognosis and there is no indication for adjuvant therapy.
  • Radically operated patients with high-risk early ovarian cancer (clear cell carcinomas or FIGO stage IA or IB moderately or poorly differentiated carcinomas or stage IC) have a substantial risk for micrometastatic disease.
  • However, the role of adjuvant chemotherapy is unclear and such therapy should, thus, only be used within clinical trials.
  • The median overall survival for patients with advanced (FIGO stages II-IV) ovarian cancer randomised to paclitaxel/platinum-containing chemotherapy in three large studies ranged between 36-39 months.
  • Compared with historical data, this represents a six to seven times longer median survival time than after surgery only.
  • In two prospective randomised trials in advanced ovarian cancer, paclitaxel in combination with cisplatin has provided a survival benefit over cyclophosphamide/cisplatin.
  • Based on these trials, paclitaxel/cisplatin is considered to be the standard treatment.
  • This choice of standard therapy might, however, be questioned based on the results of the hitherto largest randomised study in advanced ovarian cancer, ICON3, which is, as yet only available in abstract form.
  • The drug regimen in the control arms of the previous studies showing superiority of the paclitaxel-cisplatin combination may not have been the optimal non-paclitaxel platinum-containing regimen.
  • Intraperitoneal therapy with cisplatin caused improved survival compared with intravenous therapy in one ramdomised study.
  • Further studies have shown trends to better survival and longer progression-free interval with intraperitoneal therapy.
  • The accrual to studies on intraperitoneal chemotherapy has been poor reflecting that it is a cumbersome and not easily accepted treatment.
  • In advanced ovarian cancer, no convincing advantage has been shown from more dose-intensive chemotherapy, without cytokines or bone marrow stem cell support, compared with standard doses.
  • High response rates are achieved with high-dose chemotherapy with stem cell support in the salvage situation but response duration is short.
  • Phase III studies evaluating high-dose chemotherapy in the first-line situation are ongoing.
  • Until supportive controlled clinical trials are presented, high-dose chemotherapy should be confined to clinical trials.
  • Tumour response is frequently observed on re-treatment with the same drugs as given first-line in patients sensitive to first-line platinum-based chemotherapy with a long progression-free interval.
  • Thus, in these patients treatment with a platinum/paclitaxel combination might be recommended. albeit based on limited data.
  • In patients resistant to first-line therapy, a number of single agents induce tumour responses in the range of 10-30%.
  • The literature does not permit general treatment recommendations in these patients, which are recommended to be included in controlled clinical trials.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Carboplatin / administration & dosage. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Cyclophosphamide / administration & dosage. Female. Humans. Infusions, Parenteral. Neoplasm Staging. Paclitaxel / administration & dosage. Prognosis. Quality of Life. Randomized Controlled Trials as Topic. Salvage Therapy. Survival Analysis

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11441940.001).
  • [ISSN] 0284-186X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Norway
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 176
  •  go-up   go-down


6. Battaglia F, Plotti F, Zullo MA, Panici PB, Plotti G: Successful pregnancy after conservative surgery for stage IC ovarian cancer with serous borderline tumor on controlateral ovary: a case report. Gynecol Oncol; 2006 Mar;100(3):612-4
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful pregnancy after conservative surgery for stage IC ovarian cancer with serous borderline tumor on controlateral ovary: a case report.
  • BACKGROUND: In invasive ovarian cancer, fertility saving surgery is confined to early-stage and low-grade disease, and only few study reported sparing fertility up to FIGO stage IC ovarian cancer.
  • CASE: We present a rare case of a 30-year-old woman affected by IC ovarian cancer with borderline tumor on controlateral ovary who underwent "conservative" debulking surgery followed by adjuvant chemotherapy.
  • CONCLUSIONS: Nowadays, preservation of ovarian function in women with tumors in early stage should be evaluated for conservative surgery.
  • Careful follow-up is mandatory to ensure safety of this procedure.
  • [MeSH-major] Live Birth. Ovarian Neoplasms / surgery
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Female. Fertility. Humans. Pregnancy

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16249017.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Abu-Musa A, Seoud M, Hannoun A: In vitro fertilization in a patient with ovarian cancer (stage IC) following conservative surgery and chemotherapy: a case report. Eur J Gynaecol Oncol; 2008;29(4):408-10
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vitro fertilization in a patient with ovarian cancer (stage IC) following conservative surgery and chemotherapy: a case report.
  • A 30-year-old female underwent left salpingo-oophorectomy followed by chemotherapy for Stage IC adenocarcinoma of the ovary.
  • Three years later she had ovarian hyperstimulation and in vitro fertilization (OH-IVF) resulting in a singleton pregnancy.
  • In conclusion, OH-IVF may be considered in young patients with early ovarian cancer treated with conservative surgery and chemotherapy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Fertilization in Vitro. Ovarian Neoplasms / drug therapy. Pregnancy Complications, Neoplastic / drug therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Female. Humans. Paclitaxel / administration & dosage. Pregnancy. Pregnancy Outcome

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18714583.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


8. Gronlund B, Hansen HH, Høgdall C, Engelholm SA: Efficacy of low-dose topotecan in second-line treatment for patients with epithelial ovarian carcinoma. Cancer; 2002 Oct 15;95(8):1656-62
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of low-dose topotecan in second-line treatment for patients with epithelial ovarian carcinoma.
  • Food and Drug Administration-approved topotecan dose of 1.5 mg/m(2) for 5 days every 3 weeks may have limited its utility in the treatment of patients with epithelial ovarian carcinoma.
  • The objective of the study was to evaluate the treatment results and toxicity of a low-dose topotecan regimen as second-line treatment for patients with epithelial ovarian carcinoma.
  • METHODS: A retrospective analysis was conducted of 203 consecutive patients with primary epithelial ovarian carcinoma who were referred to the Finsen Center during the period from June, 1996 to June, 2000.
  • Eligibility criteria included histopathologically documented, International Federation of Gynecology and Obstetrics (FIGO) Stage IC-IV epithelial ovarian carcinoma; first-line treatment with paclitaxel and a platinum compound; and second-line treatment with topotecan (1.0 mg/m(2) intravenously for 5 days every 3 weeks).
  • RESULTS: A total of 56 patients received second-line treatment with the reduced-dose topotecan regimen because of refractory, persistent, or recurrent disease.
  • In patients with platinum-resistant and paclitaxel-resistant disease, the median progression free survival and overall survival from the first day of second-line topotecan treatment were 2.7 months (range, 0.7-19.5 months) and 6.0 months (range, 1.0-32.8 months), respectively.
  • In a multivariate Cox analysis, the initial performance status (0 vs. 1-2; P = 0.040; hazard ratio [HR], 2.05) and the performance status at the time of second-line treatment (0 vs. 1-2; P < 0.001; HR, 4.50) were identified as independent prognostic factors for overall survival from the start of second-line treatment.
  • CONCLUSIONS: Topotecan at a dose of 1.0 mg/m(2) has similar efficacy based on response rate and lower toxicity compared with the approved schedule of 1.5 mg/m(2) for 5 days every 3 weeks in second-line treatment for patients with platinum-resistant and paclitaxel-resistant epithelial ovarian carcinoma.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Antineoplastic Agents / pharmacology. Carcinoma / drug therapy. Ovarian Neoplasms / drug therapy. Topotecan / administration & dosage. Topotecan / pharmacology
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents, Phytogenic / administration & dosage. Cisplatin / pharmacology. Dose-Response Relationship, Drug. Drug Resistance, Neoplasm. Female. Humans. Middle Aged. Paclitaxel / administration & dosage. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 American Cancer Society.
  • (PMID = 12365013.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 7M7YKX2N15 / Topotecan; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


9. Furukawa M, Fujiwara H, Urabe S, Egawa M, Fujitoh N, Sakashita T, Date K, Mizunoe T, Ueda K, Urabe T: [A case of ovarian cancer with Parkinson's disease treated by combined chemotherapy with paclitaxel and carboplatin followed by surgery]. Gan To Kagaku Ryoho; 2003 Dec;30(13):2129-32
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of ovarian cancer with Parkinson's disease treated by combined chemotherapy with paclitaxel and carboplatin followed by surgery].
  • We have successfully treated an ovarian cancer patient with Parkinson's disease by paclitaxel/CBDCA combined chemotherapy after surgery.
  • The patient was a 57-year-old woman with solid and cystic ovarian tumor.
  • We operated and made a pathological diagnosis of the ovarian tumor as clear cell adenocarcinoma (FIGO stage Ic).
  • After surgery, the patient was treated with paclitaxel (260 mg [175 mg/m2]) and CBDCA (600 mg [AUC = 5]) combined chemotherapy for 5 courses.
  • During chemotherapy, she had felt the decreased efficacy of her Parkinson's disease medication.
  • We could continue chemotherapy by increasing the dose of the Parkinson's drug.
  • [MeSH-major] Adenocarcinoma, Clear Cell / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ovarian Neoplasms / drug therapy. Parkinson Disease / complications
  • [MeSH-minor] Antiparkinson Agents / administration & dosage. Area Under Curve. Carboplatin / administration & dosage. Combined Modality Therapy. Drug Administration Schedule. Female. Humans. Hysterectomy / methods. Middle Aged. Ovariectomy. Paclitaxel / administration & dosage

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Parkinson's Disease.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14712777.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antiparkinson Agents; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


10. Mangili G, Scarfone G, Gadducci A, Sigismondi C, Ferrandina G, Scibilia G, Viganò R, Tateo S, Villa A, Lorusso D: Is adjuvant chemotherapy indicated in stage I pure immature ovarian teratoma (IT)? A multicentre Italian trial in ovarian cancer (MITO-9). Gynecol Oncol; 2010 Oct;119(1):48-52
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is adjuvant chemotherapy indicated in stage I pure immature ovarian teratoma (IT)? A multicentre Italian trial in ovarian cancer (MITO-9).
  • OBJECTIVE: Conservative surgery followed by platinum-based chemotherapy is considered the standard approach for stage I immature ovarian teratoma (IT), except for stage IA G1.
  • Nevertheless the use of chemotherapy in stage IA G2-3 and IB-IC is controversial.
  • The aim of this study was to evaluate the outcome of patients with IT in order to define the role of chemotherapy in stage I disease.
  • METHODS: Twenty-eight patients with stage I IT treated in MITO centers were retrospectively reviewed.
  • Grade, stage, age, surgical and postoperative treatment were analyzed using χ(2) test and T test looking for association with recurrence.
  • FIGO stages were 19 IA, 2 IB, and 7 IC.
  • Nine patients received adjuvant chemotherapy.
  • Overall recurrence rate was 21.4% (2 in chemotherapy group and 4 in the group without treatment).
  • Recurrence rate was not significantly different according to stage, grade or adjuvant chemotherapy, whereas it was greater in the group not operated in a MITO center, not staged and of age lower than 20 years, with statistical significance.
  • At recurrence 4 patients presenting with mature teratoma were treated with surgery alone, whereas 2 recurring with IT were treated with surgery plus chemotherapy.
  • CONCLUSIONS: Our study suggests that chemotherapy may be withheld for primary therapy and utilized only for recurrence.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ovarian Neoplasms / drug therapy. Teratoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Bleomycin / administration & dosage. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Etoposide / administration & dosage. Female. Follow-Up Studies. Humans. Middle Aged. Neoplasm Staging. Retrospective Studies. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20599258.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


11. Protopapas A, Diakomanolis E, Bamias A, Milingos S, Markaki S, Papadimitriou C, Dimopoulos AM, Michalas S: The prognostic significance of the immunohistochemical expression of p53, bcl-2, c-erb B-2 and cathepsin-D in ovarian cancer patients receiving platinum with cyclophosphamide or paclitaxel chemotherapy. Eur J Gynaecol Oncol; 2004;25(2):225-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The prognostic significance of the immunohistochemical expression of p53, bcl-2, c-erb B-2 and cathepsin-D in ovarian cancer patients receiving platinum with cyclophosphamide or paclitaxel chemotherapy.
  • PURPOSE: To evaluate the prognostic significance of the immunohistochemical expression of p53, bcl-2, c-erbB-2 and cathepsin-D in epithelial ovarian cancer (EOC).
  • METHODS: We analyzed 100 patients with ovarian carcinoma, FIGO Stage IC-IV who underwent primary cytoreductive surgery and received adjuvant chemotherapy with cyclophosphamide and a platinum analogue (CP) (n = 46) or paclitaxel and a platinum analogue (TP) (n = 54).
  • Immunohistochemical expression was studied on paraffin-embedded tissue from the primary tumor.
  • FIGO stage (p = 0.006) and histology (p = 0.047) were the only independent prognostic factors for survival.
  • CONCLUSION: Bcl-2 and cathepsin D expression are associated with response to CP but not TP chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / metabolism. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / metabolism. Adenocarcinoma, Clear Cell / mortality. Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / mortality. Adenocarcinoma, Mucinous / pathology. Carcinoma, Endometrioid / drug therapy. Carcinoma, Endometrioid / metabolism. Carcinoma, Endometrioid / mortality. Carcinoma, Endometrioid / pathology. Cathepsin D / metabolism. Cyclophosphamide / administration & dosage. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / mortality. Cystadenocarcinoma, Serous / pathology. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Paclitaxel / administration & dosage. Platinum / administration & dosage. Predictive Value of Tests. Prognosis. Proto-Oncogene Proteins c-bcl-2 / metabolism. Receptor, ErbB-2 / metabolism. Survival Analysis. Tumor Suppressor Protein p53 / metabolism

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PLATINUM .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15032288.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53; 49DFR088MY / Platinum; 8N3DW7272P / Cyclophosphamide; EC 2.7.10.1 / Receptor, ErbB-2; EC 3.4.23.5 / Cathepsin D; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


12. Numazaki R, Miyagi E, Onose R, Nakazawa T, Sugiura K, Asukai K, Nakayama H, Miyamatsu A, Okamoto N, Hirahara F: Historical control study of paclitaxel-carboplatin (TJ) versus conventional platinum-based chemotherapy (CAP) for epithelial ovarian cancer. Int J Clin Oncol; 2006 Jun;11(3):221-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Historical control study of paclitaxel-carboplatin (TJ) versus conventional platinum-based chemotherapy (CAP) for epithelial ovarian cancer.
  • BACKGROUND: As the first-line chemotherapy for epithelial ovarian cancer, the paclitaxel-carboplatin (TJ) regimen has replaced the cyclophosphamide, epirubicin, and cisplatin or carboplatin (CAP) regimen in our institutes since 1998.
  • METHODS: Women with epithelial ovarian cancer at FIGO stage Ic-IV were enrolled into the study and were assigned to either the CAP group (57 cases, from 1991 until 1998) or the TJ group (49 cases, from 1998 until 2002).
  • The response rates were 82.8% in the TJ group and 70.6% in the CAP group at stage III-IV.
  • CONCLUSION: This study demonstrated that the TJ regimen is as effective as the CAP regimen in its antitumor effect for epithelial ovarian cancer, and has controllable adverse effects.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Carboplatin / administration & dosage. Cisplatin / administration & dosage. Cyclophosphamide / administration & dosage. Cystadenocarcinoma, Serous / drug therapy. Epirubicin / administration & dosage. Female. Humans. Middle Aged. Paclitaxel / administration & dosage. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Clin Oncol. 2006 Jun;11(3):163 [16850120.001]
  • [Cites] J Natl Cancer Inst. 2000 May 3;92(9):699-708 [10793106.001]
  • [Cites] Int J Gynecol Cancer. 2001 Jul-Aug;11(4):295-9 [11520368.001]
  • [Cites] Gynecol Oncol. 2003 Aug;90(2 Pt 2):S1-7 [12927999.001]
  • [Cites] N Engl J Med. 1996 Jan 4;334(1):1-6 [7494563.001]
  • [Cites] Gynecol Oncol. 2002 May;85(2):321-6 [11972395.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Apr 1;47(1):13-47 [10758303.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3194-200 [12860964.001]
  • [Cites] Gan To Kagaku Ryoho. 2000 Dec;27(14):2259-62 [11142173.001]
  • [Cites] J Clin Oncol. 1989 Nov;7(11):1748-56 [2681557.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1 Suppl 1):20-31 [11840417.001]
  • [Cites] Acta Obstet Gynecol Scand. 1997 Aug;76(7):709-12 [9292651.001]
  • [Cites] J Clin Oncol. 1991 Jul;9(7):1138-50 [1904477.001]
  • [Cites] J Natl Cancer Inst. 2003 Sep 3;95(17):1320-9 [12953086.001]
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3084-92 [10963636.001]
  • [Cites] Cancer J. 2001 Mar-Apr;7(2):155-64 [11324769.001]
  • (PMID = 16850129.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 3Z8479ZZ5X / Epirubicin; 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


13. Kawagishi N, Shirahata Y, Ishida K, Satoh K, Enomoto Y, Akamatsu Y, Sekiguchi S, Fukumori T, Fujimori K, Satoh A, Moriya T, Satomi S: Hepatic resection of giant metastatic tumor from clear cell carcinoma of the ovary. J Hepatobiliary Pancreat Surg; 2005;12(2):155-8
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic resection of giant metastatic tumor from clear cell carcinoma of the ovary.
  • All cancer patients, particularly those treated for colorectal cancer, should be monitored for the presence of liver metastases, but liver metastases from ovarian clear cell carcinoma are quite rare.
  • We report a patient subjected to extended left hepatectomy due to a giant metastasis 5 years after surgical treatment for an ovarian neoplasm that was histopathologically diagnosed as clear cell carcinoma.
  • A 58-year-old woman had undergone hysterectomy and bilateral salpingo-oophorectomy due to ovarian cancer (stage Ic).
  • Four years and 8 months after the operation, a computed tomography (CT) scan demonstrated a giant tumor in the left lobe of the liver.
  • She received chemotherapy for 4 months; however, the tumor did not decrease in size.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / secondary. Hepatectomy. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15868082.001).
  • [ISSN] 0944-1166
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


14. Furukawa N: Solitary splenic metastasis of ovarian cancer. Arch Gynecol Obstet; 2007 Jun;275(6):499-502
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary splenic metastasis of ovarian cancer.
  • BACKGROUND: Solitary splenic metastasis occurs relatively rarely in ovarian cancer.
  • CASE REPORT: This report presents a patient in whom a solitary splenic metastasis was detected 9 years after diagnosis of stage Ic ovarian cancer.
  • The patient was a 59-year-old woman who was diagnosed with stage Ic ovarian serous cystadenocarcinoma in 1992, underwent postoperative chemotherapy, and exhibited no signs of recurrence in terms of clinical symptoms, markers and imaging findings.
  • The patient underwent a splenectomy and microscopy confirmed the splenic tumor to be of the same histological type as the ovarian cancer.
  • [MeSH-major] Cystadenocarcinoma, Serous / secondary. Ovarian Neoplasms / pathology. Splenic Neoplasms / secondary
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. CA-125 Antigen. Female. Humans. Magnetic Resonance Imaging. Middle Aged. Splenectomy

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17096159.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / CA-125 Antigen
  •  go-up   go-down


15. Sevelda P, Sevelda U, Denison U, Kaider A, Austrian Society of Gynecologic Oncology: Cytoprotection of amifostine (A) in ovarian cancer patients receiving paclitaxel/carboplatin (PC) first line chemotherapy in a multicenter phase III trial. J Clin Oncol; 2004 Jul 15;22(14_suppl):5021

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytoprotection of amifostine (A) in ovarian cancer patients receiving paclitaxel/carboplatin (PC) first line chemotherapy in a multicenter phase III trial.
  • : 5021 Background: The primary objectives of the study were to evaluate, if A can prevent or reduce the WHO grade of haematological and non haematological toxicities induced by PC and to determine if A enables to adhere to the planned chemotherapy regimen (interval and dosage).
  • METHODS: 89 patients with primary epithelial ovarian cancer FIGO Stage IC - IV were entered into this prospective randomised phase III trial between 1998 and 2/2002.
  • In all patients first line chemotherapy of P 175 mg/m<sup>2</sup> i.v. within 3 hours day 1 and C AUC 5 on day 2 was planned for 6 cycles.
  • 41 patients received chemotherapy only.
  • RESULTS: The planned number of 40 patients in each treatment arm was achieved with 85 eligible patients.
  • This number was calculated to confirm a reduction of granulocytopenia by 50% and prevention of neurotoxicity difference in score increase by 2 units) in the A therapy arm.
  • Grad 3 and 4 granulocytopenia developed in 52,3 % of the patients in the A arm and 71,8 % in the control group (one-sided chi-square test X<sup>2</sup>= 3,32; p=0,034).
  • Neurotoxicity and all other toxicities were identical in both treatment arms.
  • Only nausea and vomiting was significantly increased in the A therapy arm with 20,5% grade 3 and 4 versus 5,1% in the control arm (chi-square test X<sup>2</sup>=4,22; p= 0,04).
  • Treatment delay was not significantly different in both groups.
  • At present we cannot recommend A as standard cytoprotective agent in ovarian cancer patients treated with this PC chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28015515.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Marinaccio M, Mele E, Poma S, Cantinieri C, Cocca M, Latiano T: Pretreatment normalization of mild anemia with epoetin alfa predicts long-term outcome for women with epithelial ovarian cancer. J Clin Oncol; 2004 Jul 15;22(14_suppl):5132

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pretreatment normalization of mild anemia with epoetin alfa predicts long-term outcome for women with epithelial ovarian cancer.
  • : 5132 Background: In a previous study (Marinaccio et al. Proc.ASCO 2003;Abstr1952) we assumed that pretreatment normalization of mild anemia with epoetin alfa could improve the outcome in patients with epithelial ovarian cancer.
  • The aim of this larger trial was to understand better the influence of recombinant human erythropoietin (rHuEPO) on the outcome of ovarian cancer patients showing anemia before undergoing surgery and chemotherapy.
  • METHODS: Between 1999 and 2003, 42 patients with mild anemia (Hgb 10.6-11.9 g/dL) secondary to advanced epithelial ovarian cancer were randomized to receive epoetin alfa (21 pts.) or not (21 pts.) before primary surgery.
  • FIGO stage at diagnosis was as follows: IC 13/42; II 5/42; III 19/42; IV 5/42.
  • After surgery all patients underwent adjuvant chemotherapy with paclitaxel (175mg/mq) plus carboplatin (AUC5).
  • Patients in the treatment group were administered rHuEPO, 10.000 IU, three times a week subcutaneously for 4-6 weeks.
  • The relationship of Hgb to survival was determined by Cox Regression analysis after adjusting for the effect of known prognostic variables including FIGO stage, tumor grade and residual tumor.
  • The median relapse-free survival time was found to be 26 months in patients treated with rHuEPO and 18 months in the control arm; the evaluation of median survival time is in progress, however Kaplan-Meier 12-month estimates of survival were 65% for the rHuEPO arm and 50 % for the control arm, revealing a trend in overall survival favoring normalization of pre-treatment anemia with rHuEPO (Kaplan-Meier analysis p=0.12, Cox regression analysis p=0.044).
  • CONCLUSIONS: Pretreatment of mild anemia with epoetin alfa in patients with epithelial ovarian cancer offers an excellent possibility of improving the outcome.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016754.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Seiden MV, Benigno BB, SMART study investigator group: A pivotal phase III trial to evaluate the efficacy and safety of adjuvant treatment with R1549 (yttrium-90-labeled HMFG1 murine monoclonal antibody) in epithelial ovarian cancer (EOC). J Clin Oncol; 2004 Jul 15;22(14_suppl):5008

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A pivotal phase III trial to evaluate the efficacy and safety of adjuvant treatment with R1549 (yttrium-90-labeled HMFG1 murine monoclonal antibody) in epithelial ovarian cancer (EOC).
  • : 5008 Background: EOC patients achieving a complete response (CR) after primary therapy are at substantial risk of recurrent disease.
  • ) R1549 following standard treatment demonstrated encouraging survival compared with a historical control group.
  • METHODS: The Study of Monoclonal AntibodyRadioimmunoTherapy (SMART) is a multinational, multicenter, randomized, phase III trial comparing standard treatment plus adjuvant R1549 with standard treatment alone.
  • Patients with FIGO stage Ic-IV, MUC1-positive EOC achieving clinical CR with first-line therapy were randomized 1:1.
  • Patients with no macroscopic disease at second look laparoscopy (-ve SLL), performed 4-8 weeks after completion of chemotherapy, remained on study.
  • Patients in the active treatment arm received a single i.p. dose of 25mg R1549 (≈ 666MBq/m<sup>2</sup>; maximum dose 1110MBq); patients in the control arm received standard care.
  • The primary endpoint was length of survival; secondary endpoints included time to relapse and safety.
  • With a median follow-up of 3.5 years (range 1-6), 104 and 70 have relapsed and died in the active treatment arm (n=224), respectively, as compared with 98 and 61 in the control arm (n=223).
  • Cox proportional hazards analysis of survival and time to relapse demonstrated no difference between treatment arms.
  • Active therapy was associated with occasional, transient Grade 3/4 thrombocytopenia and neutropenia, and mild to moderate GI symptoms, abdominal discomfort, arthralgia, and myalgia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28015490.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Kaye SB, Scottish Gynaecological Cancer Trials Group: The integration of docetaxel into first-line chemotherapy for ovarian cancer. Int J Gynecol Cancer; 2001;11 Suppl 1:31-3
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The integration of docetaxel into first-line chemotherapy for ovarian cancer.
  • Docetaxel is being explored as an alternative to paclitaxel in the treatment of ovarian cancer for several reasons: a) evidence of superiority in preclinical models;.
  • c) indirect evidence of superiority in breast cancer;.
  • The Scottish Gynaecological Cancer Trials Group (SGCTG) has performed successive first-line feasibility trials of docetaxel in combination with cisplatin (100 patients) and carboplatin (141 patients).
  • This has now been completed, with 1077 patients (FIGO stage IC-IV disease) randomized, from 83 centers in 10 countries.
  • A toxicity analysis has been completed, since the last patient finished treatment in October 2000.
  • Treatment was delivered as prescribed (6 cycles) in a similar number of patients (79-84%).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ovarian Neoplasms / drug therapy. Paclitaxel / therapeutic use. Taxoids
  • [MeSH-minor] Adult. Area Under Curve. Carboplatin / pharmacokinetics. Carboplatin / therapeutic use. Cisplatin / pharmacokinetics. Cisplatin / therapeutic use. Female. Humans. Randomized Controlled Trials as Topic. Treatment Outcome

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11489000.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


19. Sugiyama T, Kamura T, Kigawa J, Terakawa N, Kikuchi Y, Kita T, Suzuki M, Sato I, Taguchi K: Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer; 2000 Jun 1;88(11):2584-9
Hazardous Substances Data Bank. PLATINUM COMPOUNDS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy.
  • BACKGROUND: A retrospective review of treatment results comparing women with clear cell carcinoma of the ovary (CCC) with a group with serous adenocarcinoma of the ovary (SAC) was conducted.
  • METHODS: Between 1988-1998, 662 patients with epithelial ovarian carcinoma were identified through the medical records department and the tumor registry at 4 institutions.
  • All patients underwent staging laparotomy followed by platinum-based chemotherapy.
  • Distribution of the International Federation of Gynecology and Obstetrics (FIGO) disease stage, response to chemotherapy, and prognosis for patients with CCC were compared with the same values in patients with SAC.
  • RESULTS: Patients with CCC were significantly more likely to have FIGO Stage I disease than were patients with SAC (48.5% vs. 16.6%).
  • A high recurrence rate was noted in those patients with Stage IC CCC (37%).
  • In those patients with Stage IC disease, the survival rates for patients with CCC were lower than those for patients with SAC.
  • The 3-year and 5-year survival rates for Stage III CCC patients were significantly lower compared with Stage III SAC patients.
  • The response rate to platinum-based chemotherapy in patients with CCC was significantly lower than that in patients with SAC.
  • CONCLUSIONS: CCC is an intriguing histologic type of epithelial ovarian cancer that demonstrates a clinical behavior distinctly different from that of SAC.
  • [MeSH-major] Adenocarcinoma, Clear Cell / mortality. Cystadenocarcinoma, Serous / mortality. Ovarian Neoplasms / mortality
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Chi-Square Distribution. Female. Humans. Middle Aged. Neoplasm Staging. Platinum Compounds / therapeutic use. Retrospective Studies. Statistics, Nonparametric. Survival Rate

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 American Cancer Society.
  • (PMID = 10861437.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Platinum Compounds
  •  go-up   go-down


20. Sueblinvong T, Noophun P, Pataradool K, Suwanwela N, Phanthumchinda K, Tresukosol D: Posterior leukoencephalopathy following cisplatin, bleomycin and vinblastine therapy for germ cell tumor of the ovary. J Obstet Gynaecol Res; 2002 Apr;28(2):99-103
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Posterior leukoencephalopathy following cisplatin, bleomycin and vinblastine therapy for germ cell tumor of the ovary.
  • A 31-year-old female developed multiple episodes of grand mal seizures after combination chemotherapy with cisplatin, vinblastine and bleomycin for germ cell ovarian cancer stage Ic.
  • The clinicoradiologic features in this patient were consistent with posterior leukoencephalopathy, which is a rare complication of chemotherapy.
  • This syndrome has been previously reported following cisplatin-based chemotherapy.
  • Physicians should remain alert to the potential hazards of chemotherapy to the central nervous system.
  • Risks and benefits should be seriously considered before starting treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Brain Diseases / chemically induced. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Adult. Anticonvulsants / therapeutic use. Bleomycin / adverse effects. Cisplatin / adverse effects. Electroencephalography. Female. Humans. Magnetic Resonance Imaging. Phenytoin / therapeutic use. Seizures / drug therapy. Seizures / etiology. Tomography, X-Ray Computed. Vinblastine / adverse effects

  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. PHENYTOIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12078977.001).
  • [ISSN] 1341-8076
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Anticonvulsants; 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; 6158TKW0C5 / Phenytoin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


21. du Bois A, Belau A, Wagner U, Pfisterer J, Schmalfeldt B, Richter B, Staehle A, Jackisch C, Lueck HJ, Schroeder W, Burges A, Olbricht S, Elser G, Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR): A phase II study of paclitaxel, carboplatin, and gemcitabine in previously untreated patients with epithelial ovarian cancer FIGO stage IC-IV (AGO-OVAR protocol OVAR-8). Gynecol Oncol; 2005 Feb;96(2):444-51
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of paclitaxel, carboplatin, and gemcitabine in previously untreated patients with epithelial ovarian cancer FIGO stage IC-IV (AGO-OVAR protocol OVAR-8).
  • PURPOSE: A multicenter, nonrandomized, phase II study was initiated to evaluate the tolerability, toxicity, and activity of paclitaxel, carboplatin, and gemcitabine combination in previously untreated ovarian cancer.
  • PATIENTS AND METHODS: Chemonaive patients who had radical debulking surgery for primary epithelial ovarian cancer International Federation of Gynecology and Obstetrics (FIGO) IC-IV received sequentially paclitaxel 175 mg/m(2), carboplatin AUC 5, and gemcitabine 800 mg/m(2) on day 1 and gemcitabine 800 mg/m(2) on day 8, every 3 weeks.
  • Toxicity-induced treatment delays occurred in 3.1% of cycles and resulted in early treatment cessation in four patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Deoxycytidine / analogs & derivatives. Ovarian Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15661234.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


22. Morice P, Leblanc E, Rey A, Baron M, Querleu D, Blanchot J, Duvillard P, Lhommé C, Castaigne D, Classe JM, Bonnier P, GCCLCC and SFOG: Conservative treatment in epithelial ovarian cancer: results of a multicentre study of the GCCLCC (Groupe des Chirurgiens de Centre de Lutte Contre le Cancer) and SFOG (Société Francaise d'Oncologie Gynécologique). Hum Reprod; 2005 May;20(5):1379-85
Hazardous Substances Data Bank. PLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conservative treatment in epithelial ovarian cancer: results of a multicentre study of the GCCLCC (Groupe des Chirurgiens de Centre de Lutte Contre le Cancer) and SFOG (Société Francaise d'Oncologie Gynécologique).
  • BACKGROUND: Results of conservative management of epithelial ovarian cancer (EOC) remain controversial in the literature.
  • (v) delivery of a platinum-based chemotherapy in stage > or = IC; and (vi) follow-up >1 year.
  • RESULTS: Thirty-four patients fulfilled the inclusion criteria: 30 had stage IA disease; three had stage IC and one had stage IIA.
  • Among 10 patients with invasive recurrence, initial stage and grade were: stage IA G1, n = 1; stage IA G2, n = 4; stage IA G3, n = 1; and stage> or = IC, n = 4.
  • All patients with stage > IA had recurrence.
  • CONCLUSION: Conservative surgery for patients with EOC could be considered in young patients with stage IA G1 disease.
  • This procedure should not be performed in patients with FIGO stage > IA.
  • [MeSH-major] Neoplasms, Glandular and Epithelial / drug therapy. Neoplasms, Glandular and Epithelial / pathology. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / therapeutic use. Female. Fertility / physiology. Follow-Up Studies. Humans. Hysterectomy. Neoplasm Recurrence, Local. Neoplasm Staging. Ovary / physiology. Platinum / therapeutic use. Pregnancy. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15817592.001).
  • [ISSN] 0268-1161
  • [Journal-full-title] Human reproduction (Oxford, England)
  • [ISO-abbreviation] Hum. Reprod.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 49DFR088MY / Platinum
  •  go-up   go-down


23. Borgfeldt C, Iosif C, Måsbäck A: Fertility-sparing surgery and outcome in fertile women with ovarian borderline tumors and epithelial invasive ovarian cancer. Eur J Obstet Gynecol Reprod Biol; 2007 Sep;134(1):110-4
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fertility-sparing surgery and outcome in fertile women with ovarian borderline tumors and epithelial invasive ovarian cancer.
  • OBJECTIVE: The aim was to evaluate the outcome of fertility-sparing treatment in ovarian borderline tumors and early invasive ovarian cancer.
  • MATERIALS AND METHODS: All women diagnosed with an ovarian borderline tumor or early invasive ovarian cancer who were treated with fertility-sparing surgery at the University Hospital in Lund between 1988 and 2002 were identified and included in the study (n=23).
  • RESULTS: During the follow-up period of a median 92 months, range 11-185 months, no relapse was found in the patients with Stage 1a tumors, including both borderline tumors (n=12) and invasive well-differentiated (n=9) and moderately differentiated (n=1) ovarian cancers.
  • One patient with poorly differentiated ovarian cancer Stage 1c was 13 weeks' pregnant at the time of the primary operation.
  • At 37 weeks she had a cesarean section and the ovarian cancer was disseminated.
  • Chemotherapy was given but she died less than a year later.
  • None of the other patients received chemotherapy.
  • Prophylactic removal of the remaining ovary+/-hysterectomy was accepted in only in six of the women after fulfilling their desire to have more children.
  • CONCLUSIONS: Young women with Stage 1a epithelial ovarian cancer and borderline tumors do not have to give up their fertility in order to receive successful and safe treatment of their disease.
  • However, several of these patients do not accept the recommendation of prophylactic oophorectomy of the contralateral ovary and hysterectomy after completion of childbearing.
  • [MeSH-major] Adenocarcinoma / surgery. Fertility. Ovarian Neoplasms / surgery. Ovariectomy / methods

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16859821.001).
  • [ISSN] 0301-2115
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


24. Gronlund B, Høgdall C, Christensen IJ, Engelholm SA, Hansen HH: Is stabilization of disease a useful indicator for survival in second-line treatment of ovarian carcinoma pre-treated with Paclitaxel-Platinum? Gynecol Oncol; 2004 Aug;94(2):409-15
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is stabilization of disease a useful indicator for survival in second-line treatment of ovarian carcinoma pre-treated with Paclitaxel-Platinum?
  • OBJECTIVE: Recurrent ovarian carcinoma is considered an incurable disease and second-line chemotherapy is administered for extension of survival and palliation.
  • The impact of continued antineoplastic treatment in patients with stable disease without a demonstrable response is uncertain.
  • The aim of this analysis was to assess the value of a stabilization of the tumor size in second-line chemotherapy as an indicator of survival.
  • METHODS: Retrospective, single-institution study of 487 consecutive patients with primary epithelial ovarian carcinoma.
  • (1) FIGO stage IC-IV epithelial ovarian carcinoma;.
  • (2) first-line chemotherapy with Paclitaxel and a Platinum-compound;.
  • (3) refractory, persistent, or recurrent disease diagnosed by imaging methods; and (4) intravenous second-line chemotherapy with single Topotecan or Paclitaxel-Carboplatin.
  • Univariate and multivariate analyses of survival with the World Health Organization (WHO) tumor response parameter included as a time-dependent variable were performed.
  • CONCLUSION: In second-line chemotherapy of ovarian cancer, patients demonstrating SD have a survival benefit compared to patients with PD measured by the WHO tumor response criteria.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Ovarian Neoplasms / drug therapy. Topotecan / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15297181.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 7M7YKX2N15 / Topotecan; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


25. Muzii L, Palaia I, Sansone M, Calcagno M, Plotti F, Angioli R, Panici PB: Laparoscopic fertility-sparing staging in unexpected early stage ovarian malignancies. Fertil Steril; 2009 Jun;91(6):2632-7
MedlinePlus Health Information. consumer health - Ovarian Cysts.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic fertility-sparing staging in unexpected early stage ovarian malignancies.
  • OBJECTIVE: To assess feasibility and safety of fertility-sparing laparoscopic staging in women affected by unexpected ovarian cancer desiring to preserve their fertility.
  • PATIENT(S): Twenty-seven patients already operated on elsewhere for a presumably benign ovarian cyst.
  • RESULT(S): Histologic findings after first surgery: 12 low malignant potential neoplasms, 11 invasive epithelial ovarian carcinomas,1 sex-cord stromal, and 3 germ cell neoplasms.
  • Fertility-sparing staging consisted of exploration of the peritoneal cavity, peritoneal washing cytology, multiple peritoneal biopsies, omolateral adnexectomy (except in borderline tumors), omentectomy, omolateral or bilateral pelvic and aortic lymph node sampling (except in borderline tumors, well differentiated, mucinous, and granulosa cell (GC) neoplasms), endometrial biopsy, appendectomy in mucinous type.
  • Six patients received adjuvant platinum-based chemotherapy.
  • After a median follow-up of 20 months all patients are alive; one patient has FIGO stage Ic clear cell carcinoma, which recurred 8 months after surgery.
  • CONCLUSION(S): Laparoscopic fertility-sparing staging in early ovarian malignancies is feasible and safe in selected and counseled patients and should be performed in experienced gynecological oncology centers trained in endoscopic procedures.
  • [MeSH-major] Fertility / physiology. Laparoscopy / methods. Ovarian Cysts / surgery. Ovarian Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18555237.001).
  • [ISSN] 1556-5653
  • [Journal-full-title] Fertility and sterility
  • [ISO-abbreviation] Fertil. Steril.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Sayedur Rahman M, Al-Sibai MH, Rahman J, Al-Suleiman SA, El-Yahia AR, Al-Mulhim AA, Al-Jama F: Ovarian carcinoma associated with pregnancy. A review of 9 cases. Acta Obstet Gynecol Scand; 2002 Mar;81(3):260-4
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian carcinoma associated with pregnancy. A review of 9 cases.
  • BACKGROUND: The purpose of this study was to review patients with ovarian cancer in pregnancy, the effectiveness of the available methods of treatment and their prognosis.
  • METHODS: A retrospective review of all women diagnosed to have cancer of the ovary associated with pregnancy who delivered at the authors' hospitals between January 1976 and December 2000.
  • The demography, clinical presentation, time and mode of diagnosis, treatment, pregnancy outcome and maternal survival were noted.
  • RESULTS: The incidence of ovarian carcinoma in pregnancy in the series was 0.08/1000 deliveries.
  • Of the 9 patients, 7 had epithelial cancers; 4 serous cystadenocarcinoma, 2 mucinous cystadenocarcinomas and one undifferentiated cancer.
  • Six patients were in FIGO stage Ia, one Ic, one IIa.
  • One patient was in stage III.
  • Three patients had total abdominal hysterectomy, bilateral salpingo-oophorectomy and omentectomy followed by chemotherapy.
  • Debulking of the tumor was done in a patient in stage III with subsequent chemotherapy.
  • This patient died 13 months from the time of diagnosis of the tumor.
  • The overall 5-year survival rate in the series was 78% and 100% for stage Ia.
  • CONCLUSIONS: Association of ovarian cancer with pregnancy is a rare occurrence.
  • Early diagnosis and appropriate treatment offers the best prognosis for the patient.
  • The higher survival rates in the series was attributed to a larger number of patients in stage I of the disease and 2 patients with a germ cell tumor and dysgerminoma which have the best prognosis.
  • Aggressive postoperative chemotherapy also contributed to the better outcome.
  • [MeSH-major] Carcinoma / complications. Carcinoma / therapy. Ovarian Neoplasms / complications. Ovarian Neoplasms / therapy. Pregnancy Complications, Neoplastic / mortality. Pregnancy Complications, Neoplastic / therapy

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11966485.001).
  • [ISSN] 0001-6349
  • [Journal-full-title] Acta obstetricia et gynecologica Scandinavica
  • [ISO-abbreviation] Acta Obstet Gynecol Scand
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Denmark
  • [Number-of-references] 15
  •  go-up   go-down


27. Wong HF, Low JJ, Chua Y, Busmanis I, Tay EH, Ho TH: Ovarian tumors of borderline malignancy: a review of 247 patients from 1991 to 2004. Int J Gynecol Cancer; 2007 Mar-Apr;17(2):342-9
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian tumors of borderline malignancy: a review of 247 patients from 1991 to 2004.
  • Borderline ovarian tumors account for 15% of epithelial ovarian cancers and are different from invasive malignant carcinoma.
  • Majority are early stage, occurring in women in the reproductive age group, where fertility is important.
  • Majority of the cases (92%) were FIGO stage I (Ia, 75%; Ib, 1%; and Ic, 16%).
  • Seven (3.5%) patients were diagnosed as having stage II disease, six (2.5%) as stage IIIa, two (1%) as stage IIIb, and four (2%) as stage IIIc.
  • Primary surgical procedures undertaken were as follows: hysterectomy with bilateral salpingo-oophorectomy (52%), unilateral salpingo-oophorectomy (33%), or ovarian cystectomy (15%).
  • Adjuvant chemotherapy was administered in 13 patients (5.2% of cases), of which 4 patients were given chemotherapy only because of synchronous malignancies.
  • Overall mean time to recurrence was 59 months.
  • There were a total of five deaths (2.8%): three (1.5%) from invasive ovarian/peritoneal carcinoma and two from synchronous uterine malignancies.
  • It appears that surgical resection is the mainstay of treatment, with conservative surgery where fertility is desired or pelvic clearance if the family is complete.
  • The role of adjuvant chemotherapy is not established.
  • [MeSH-major] Neoplasms, Glandular and Epithelial / pathology. Ovarian Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17343573.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. O'Malley CD, Cress RD, Campleman SL, Leiserowitz GS: Survival of Californian women with epithelial ovarian cancer, 1994-1996: a population-based study. Gynecol Oncol; 2003 Dec;91(3):608-15
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival of Californian women with epithelial ovarian cancer, 1994-1996: a population-based study.
  • OBJECTIVE: The objective was to identify demographic, clinical, and provider characteristics that might influence cancer survival in a cohort of Northern California women using a population-based cancer registry.
  • METHODS: We used California Cancer Registry data to evaluate survival in 1051 Northern California women who were diagnosed with epithelial ovarian cancer between 1994 and 1996 and underwent a surgical procedure for their cancer.
  • Chemotherapy data from the cancer registry were supplemented with a physician survey and medical record review.
  • RESULTS: Crude 5-year survival was 82, 57, 28, and 10% for women with FIGO stage IC, II, III, and IV disease, respectively.
  • Adverse survival was most strongly influenced by advanced stages III and IV with a hazards ratio ranging from 8 to 11.8 compared to stage IC disease.
  • Chemotherapy decreased the risk of death by 50% if the patient had advanced-stage disease.
  • CONCLUSION: Advanced age remains an adverse prognostic factor even after adjustment for treatment and comorbidity factors.
  • These results also suggest that there may be important regional differences in ovarian cancer survival.
  • [MeSH-major] Ovarian Neoplasms / mortality

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14675685.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / PC / N01-PC-65107
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


29. Ma SK, Zhang HT, Wu LY, Liu LY: [Prognostic analysis of 88 patients with ovarian clear cell carcinoma]. Zhonghua Zhong Liu Za Zhi; 2007 Oct;29(10):784-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic analysis of 88 patients with ovarian clear cell carcinoma].
  • OBJECTIVE: To investigate the clinical characteristics of clear cell carcinoma of the ovary and to compare the survival of the patients treated by three different chemotherapy regimens.
  • METHODS: Between 1984 and 2005, the clinical data of 88 surgically treated patients with clear cell carcinoma of the ovary were retrospectively analyzed.
  • Of the 88 patients, 55 (62.5%) had tumor in stage I, 2 in stage II, 22 in stage II, 3 in stage IV and 6 in indefinite stage.
  • Of 55 stage I patients, 20 received pelvic lymohadenectomy.
  • All patients were given postoperative chemotherapy, 43 patients received CAP/CP, 33 paclitaxel combination with carboplatinum/cisplatin (TC/TP) and 12 CPT-11 plus MMC.
  • During follow-up, 47 (53.4%) patients were found to have recurrence, it was 45.4% (25/55) in stage I patients including 29.6% (8/27) in stage I a + I b and 60.7% (17/28) in stage I c, 75.0% (18/24) in stage II + III and 4/6 in the indefinite FIGO stage.
  • The recurrences rate was 27.8% (5/18) in stage I patients with pelvic lymphadenectomy vs. 51.3% (19/37) in those without.
  • The overall 3- and 5-year survival rate of 88 patients was 48.7% and 40.9% , respectively, with 72.5% and 66.8% in stage I, 100.0% and 70.5% in stage Ia + Ib, 68.5% and 60.3% in stage Ic, 41.8% and 20.8% in stage II + III, 0 in stage IV (P < 0.05).
  • The 3- and 5-year survival in stage I with pelvic lymphadenectomy was 88.5% and 75.8% vs. 70.3% and 65.1% in those without (P < 0.05).
  • CONCLUSION: Our data show that ovarian clear cell cancer patient have a poor response to CAP/CP and may have a better response to TC/TP, especially to CPT-11 plus MMC.
  • [MeSH-major] Adenocarcinoma, Clear Cell. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ovarian Neoplasms. Ovariectomy / methods

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18396695.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CA-125 Antigen
  •  go-up   go-down


30. Ma SK, Zhang HT, Sun YC, Wu LY: [Synchronous primary cancers of the endometrium and ovary: review of 43 cases]. Zhonghua Zhong Liu Za Zhi; 2008 Sep;30(9):690-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Synchronous primary cancers of the endometrium and ovary: review of 43 cases].
  • OBJECTIVE: To investigate the clinical and pathological characteristics, treatment methods, and prognosis of synchronous primary cancers of the endometrium and ovary.
  • METHODS: The clinical data of 43 patients with synchronous primary cancers of the endometrium and ovary were retrospectively reviewed.
  • FIGO stages of endometrial carcinomas: IA 18 cases, IB 20 cases, IC 2 cases, IIA 3 cases; Stages of ovarian carcinomas: IA 19 cases, IB 4 cases, IC 7 cases, II 4 cases, III C 9 cases.
  • Twenty-four patients (55.8%) were in stage I both endometrial and ovarian carcinomas.
  • The predominant ovarian histology was endometrioid or mixed tumor with endometrioid components (30/43, 69.8%).
  • Postoperatively, 26 patients (60.5%) received adjuvant chemotherapy alone, 12 had chemotherapy plus radiotherapy, only one patient had radiation alone and the remaining 4 cases received no adjuvant treatment.
  • The 3- and 5-year survival rates of patients with both endometrioid and ovarian carcinomas were higher than that of those with non-endometrioid or mixed subtypes (93.8%, 82.0% vs. 79.7%, 69.0%).
  • The 3-year and 5-year survival rates of patients with early stage disease were better than those of the other patients (93.3%, 93.3% vs. 69.7%, 36.7%).
  • Recurrence developed in 15 patients (34.9%).
  • It was showed by univariate analysis that lower CA125 level, early FIGO stage, and adjuvant chemotherapy plus radiotherapy significantly and positively affect the 5-year survival rates, while only early FIGO stage and chemotherapy plus radiotherapy were revealed by multivariate analysis as independent prognostic factors.
  • CONCLUSION: Synchronous primary cancers of the endometrium and ovary are different from either primary endometrial carcinoma or ovarian cancer, while it can usually be detected in early stage and with a good prognosis.
  • Surgical treatment alone may be enough for early stage patients.
  • Chemotherapy plus radiotherapy may be necessary for advanced stage patients.
  • [MeSH-major] Carcinoma, Endometrioid. Endometrial Neoplasms. Hysterectomy / methods. Neoplasms, Multiple Primary. Ovarian Neoplasms
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Female. Humans. Lymph Node Excision. Lymphatic Metastasis. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Proportional Hazards Models. Proteins / metabolism. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19173912.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / NBR1 protein, human; 0 / Proteins
  •  go-up   go-down


31. Gronlund B, Høgdall C, Hansen HH, Engelholm SA: Performance status rather than age is the key prognostic factor in second-line treatment of elderly patients with epithelial ovarian carcinoma. Cancer; 2002 Apr 1;94(7):1961-7
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Performance status rather than age is the key prognostic factor in second-line treatment of elderly patients with epithelial ovarian carcinoma.
  • BACKGROUND: Intravenous cytostatic agents as second-line treatment of epithelial ovarian carcinoma have been withheld from many elderly patients because of fear of toxicity.
  • The purpose of the study is to compare the toxicity and efficacy between elderly (older than 65 years of age) and younger (younger than 65 years of age) patients receiving intravenous second-line treatment of epithelial ovarian carcinoma.
  • METHODS: This study was a retrospective analysis of 286 consecutive patients with primary epithelial ovarian carcinoma.
  • Inclusion criteria included histopathologically documented International Federation of Gynecology and Obstetrics (FIGO) Stage IC-IV epithelial ovarian carcinoma; first-line treatment with paclitaxel and a platinum analog; intravenous second-line treatment with topotecan 1.0 mg/m(2)/day for 5 days, every 3 weeks or paclitaxel (175 mg/m(2)) and carboplatin (AUC 5), every 3 weeks.
  • The patients' age at start of second-line treatment in the younger (n = 68) and the elderly (n = 34) group were median 54.0 years (range, 34.7-64.3) and 69.5 years (range, 65.1-77.2), respectively.
  • The overall survival from the first day of second-line treatment in patients aged younger and older than 65 years were median 13.3+ months (range, 1.2-38.3+) and 11.8+ months (range, 2.0-41.0+), respectively (P = 0.25).
  • In a multivariate Cox analysis, performance status at time of first-line treatment (0 vs.1-2; P = 0.013; hazard ratio [HR], 2.12), performance status at time of second-line treatment (0 vs. 1-2; P = 0.004; HR, 2.47), and response to second-line treatment (CR + PR vs. NC + PD; P < 0.001; HR, 4.38) were found to be independent significant factors for overall survival whereas age (younger than 65 years vs. older than 65 years) yielded no independent information (P = 0.90).
  • No differences in the rate of postponement of treatment, neutropenia Grade 4, thrombocytopenia Grade 3-4, nor hypersensitivity reaction to either cytostatic agent between older and younger patients were noticed (P > 0.05).
  • CONCLUSIONS: Modality of second-line treatment of epithelial ovarian carcinoma should be determined more by assessment of performance status than age per se.
  • Second-line treatment with topotecan or paclitaxel-carboplatin can be safely administered in the aged.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Age Factors. Aged. Aging / physiology. Carboplatin / administration & dosage. Carboplatin / adverse effects. Epithelial Cells / pathology. Female. Humans. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Paclitaxel / administration & dosage. Paclitaxel / adverse effects. Retrospective Studies. Survival Rate. Topotecan / administration & dosage. Topotecan / adverse effects

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 American Cancer Society.
  • (PMID = 11932898.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 7M7YKX2N15 / Topotecan; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down






Advertisement